Strategies to Overcome Antimicrobial Resistance in Nosocomial Infections, A Review and Update
Authors:
- 1 September 2024
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Infectious Disorders - Drug Targets
- Vol. 24 (6) , 1-14
Abstract
Nosocomial infections, also known as healthcare-associated infections, are a significant global concern due to their strong association with high mortality and morbidity in both developed and developing countries. These infections are caused by a variety of pathogens, particularly the ESKAPE group of bacteria, which includes the six pathogens Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. These bacteria have demonstrated noteworthy resistance to different antibiotics. : Antimicrobial resistance mechanisms can manifest in various forms, including restricting drug uptake, modifying drug targets, inactivating drugs, active drug efflux, and biofilm formation. Accordingly, various strategies have been developed to combat antibiotic-resistant bacteria. These strategies encompass the development of new antibiotics, the utilization of bacteriophages that specifically target these bacteria, antimicrobial combination therapy and the use of peptides or enzymes that target the genomes or essential proteins of resistant bacteria. : Among promising approaches to overcome antibiotic resistance, the CRISPR/Cas system stands out and offers many advantages. This system enables precise and efficient editing of genetic material at specific locations in the genome. Functioning as a bacterial "adaptive immune system," the CRISPR/Cas system recognizes, degrades, and remembers foreign DNA sequences through the use of spacer DNA segments that are transcribed into CRISPR RNAs (crRNA). : This paper has focused on nosocomial infections, specifically the pathogens involved in hospital infections, the mechanisms underlying bacterial resistance, and the strategies currently employed to address this issue. Special emphasis has been placed on the application of CRISPR/Cas technology for overcoming antimicrobial resistance.Keywords
Funding Information
- Drug Applied Research Center, Tabriz University of Medical Science, Tabriz, Iran (71370)
This publication has 140 references indexed in Scilit:
- The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An UpdateDrugs, 2021
- Percutaneous transthoracic catheter drainage for lung abscess: a systematic review and meta-analysisEuropean Radiology, 2021
- Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysisCochrane Database of Systematic Reviews, 2020
- CRISPR/Cas gene therapyJournal of Cellular Physiology, 2020
- CRISPR‐Cas system: Toward a more efficient technology for genome editing and beyondJournal of Cellular Biochemistry, 2019
- Control of hospital acquired infections and antimicrobial resistance in Europe: the way to goWiener Medizinische Wochenschrift, 2019
- Characterization of β-lactamase- and efflux pump-mediated multiple antibiotic resistance in Salmonella TyphimuriumFood Science and Biotechnology, 2018
- Immunopathogenesis of Staphylococcus aureus pulmonary infectionSeminars in Immunopathology, 2011
- Trends in Antibacterial Use in US Academic Health CentersArchives of internal medicine (1960), 2008
- Bacterial resistance to antibiotics: Active efflux and reduced uptakeAdvanced Drug Delivery Reviews, 2005